Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Jones

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Leukemia Research|March 15, 2008
Altered gene expression in busulfan-resistant human myeloid leukemiaBenigno C Valdez, David Murray, Latha Ramdas, et al.
Human Fertility (Cambridge, England)|January 6, 2006
The spermatozoon at fertilisation: current understanding and future research directionsIan A Brewis, Renske A Van Gestel, Barend M Gadella, et al.
Trials|May 29, 2013
Goal-oriented cognitive rehabilitation in early-stage dementia: study protocol for a multi-centre single-blind randomised controlled trial (GREAT)Linda Clare, Antony Bayer, Alistair Burns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 27, 2004
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapyYee Chung Cheng, Gabriela Rondón, Ying Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 20, 2003
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefitBorje S Andersson, Ashwin Kashyap, Daniel Couriel, et al.
Journal of Psychopharmacology (Oxford, England)|January 21, 2017
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for PsychopharmacologyJohn T O'Brien, Clive Holmes, Matthew Jones, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 27, 2011
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomesPartow Kebriaei, Rima Saliba, Gabriela Rondon, et al.
Leukemia & Lymphoma|December 3, 2011
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer CenterPaolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Leukemia Research|March 15, 2008
Altered gene expression in busulfan-resistant human myeloid leukemiaBenigno C Valdez, David Murray, Latha Ramdas, et al.
Human Fertility (Cambridge, England)|January 6, 2006
The spermatozoon at fertilisation: current understanding and future research directionsIan A Brewis, Renske A Van Gestel, Barend M Gadella, et al.
Trials|May 29, 2013
Goal-oriented cognitive rehabilitation in early-stage dementia: study protocol for a multi-centre single-blind randomised controlled trial (GREAT)Linda Clare, Antony Bayer, Alistair Burns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 27, 2004
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapyYee Chung Cheng, Gabriela Rondón, Ying Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 20, 2003
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefitBorje S Andersson, Ashwin Kashyap, Daniel Couriel, et al.
Journal of Psychopharmacology (Oxford, England)|January 21, 2017
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for PsychopharmacologyJohn T O'Brien, Clive Holmes, Matthew Jones, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 27, 2011
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomesPartow Kebriaei, Rima Saliba, Gabriela Rondon, et al.
Leukemia & Lymphoma|December 3, 2011
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer CenterPaolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Pageof 9